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Mutations inp53andRASpotently cooperate inonco-
genic transformation, and correspondingly, these
genetic alterations frequently coexist in pancreatic
ductal adenocarcinoma (PDA) and other human can-
cers. Previously,we identifiedasetof genes synergis-
tically activated by combinedRAS and p53mutations
as frequent downstream mediators of tumorigen-
esis. Here, we show that the synergistically activated
gene Plac8 is critical for pancreatic cancer growth.
Silencing of Plac8 in cell lines suppresses tumor for-
mation by blocking autophagy, a process essential
for maintaining metabolic homeostasis in PDA, and
genetic inactivation in an engineered mouse model
inhibitsPDAprogression.WeshowthatPlac8 is a crit-
ical regulator of the autophagic machinery, localizing
to the lysosomal compartment and facilitating lyso-
some-autophagosome fusion. Plac8 thus provides
a mechanistic link between primary oncogenic muta-
tions and the induction of autophagy, a central mech-
anism of metabolic reprogramming, during PDA
progression.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) depends on a marked
reprogramming of metabolic pathways, including the acquisition
of autophagy dependence, for tumor cell survival and growth
(Guo et al., 2011; Lock et al., 2011; Yang et al., 2011; Ying
et al., 2012). Autophagy (or macroautophagy) is the process of
autodigestion that recycles damaged organelles and enables
cells to combat oxidative and nutrient stress and appears to
have a context-dependent role in cancer. A present model sug-
gests that autophagy has a dual role in cancer; suppressing can-
cer progression at its earliest stages, while allowing advancedCcancers to meet metabolic demands (Kimmelman, 2011; White,
2012). Consistent with this, PDA and other tumor cell lines show
constitutive basal autophagy in normal growth media, and phar-
macologic or genetic blockade of autophagy strongly impairs
tumor growth of xenograft models (Guo et al., 2011; Lock
et al., 2011; O’Dell et al., 2012; Yang et al., 2011).
The spectrum of mutational events in PDA is well defined with
activating RAS mutations present in most tumors (93%) and
common inactivating mutational events in TP53, CDKN2A, and
SMAD4 tumor suppressors and associated pathway compo-
nents (Biankin et al., 2012). Analysis of human PDA pathological
precursors, together with studies in genetically engineeredmice,
have established activating RAS mutations as a critical early
events in PDA pathogenesis with cooperating loss of tumor sup-
pressors genes occurring later (Aguirre et al., 2003; Bardeesy
et al., 2006a; Hingorani et al., 2003; Hruban et al., 2001). How
these mutational events in PDA cause autophagy dependence
and the timing of autophagy activation in the course of cancer
progression have not been established. Among the commonly
mutated genes in PDA, RAS has been associated with auto-
phagy activation, though not all RASmutant tumor demonstrate
autophagy dependence (Guo et al., 2011; Yang et al., 2011).
Inactivation of the p53-p19Arf tumor suppressor axis has also
been implicated in autophagy control with differing effects de-
pending on the experimental context (Balaburski et al., 2010;
Feng et al., 2005; Pimkina and Murphy, 2009; Tasdemir et al.,
2008). The roles of these primary oncogenicmutations in causing
autophagy activation in PDA, and a molecular basis for this phe-
nomenon, thus remain unclear.
Previously, we have shown that genes regulated synergisti-
cally in response to common cooperating oncogenic mutations
found in PDA (RAS activation and functional loss of p53) are
causally linked to the cancer phenotype. These genes, termed
‘‘cooperation response genes’’ (CRGs), encompass a spectrum
of cellular processes down-stream of oncogenic mutations that
are required for RAS/p53-mediated tumorigenesis (McMurray
et al., 2008; Smith and Land, 2012). Here, we show that one
such CRG, Plac8 is upregulated by cooperating RAS and p53ell Reports 7, 1143–1155, May 22, 2014 ª2014 The Authors 1143
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B Figure 1. Plac8 Expression Induced byOncogenic Mutations Is Critical for Growth
of Human Xenograft PDA Cell Lines and Is
Localized to the Lysosome Compartment
(A) Immunoblotting of murine YAMC, vector, mp53,
Ras, and mp53/Ras transformed cells with anti-
Plac8 antibody.
(B) Immunoblotting of human PDA cell lines
including CAPAN-2 cells stably infected with Plac8
shRNA expressing vector or control with anti-Plac8
antibody and b-tubulin (loading control).
(C) Vector control and Plac8 KD CAPAN-2 cells
were injected into CD-1 nude mice, and vector
control and Plac8 KD PANC-1 and Panc10.05 cell
lines were injected into NOD/SCID mice. Data are
presented as means ± SD (significance by Stu-
dent’s t test, ***p < 0.001).
(D) mp53/Ras murine cells were fixed and stained
using anti-Plac8 and anti-Lamp2 antibodies and
imaged by confocal microscopy.
(E) Subcellular fractionation and immunoblotting
of mp53/Ras transformed murine cells for Plac8,
lysosomal proteins Rab7 and Lamp2, autophago-
somal protein LC3, and a cytosolic control RhoA.
Lanes are as follows: WC (1): whole-cell lysate,
N(2): nuclear fraction, C(3): cytosolic fraction,
CL(4): crude lysosomal fraction, M(5): microsomal
fraction, L(6): lysosomal fraction.
(F) Cytosolic fractions (C) and crude lysosomal
fractions (CL) were isolated frommp53/Rasmurine
cells and the crude lysosomal fraction subjected to
a Proteinase K protection assay. Lysosomes were
treated with Proteinase or treated with Proteinase
K and Triton X-100 to dissolve the lysosomal
membrane and immunoblotted for the external
lysosomal protein Rab7, internal lysosomal pro-
teins Lamp2 and Cathepsin D, and Plac8. RhoA
served as a cytosolic fraction control.mutations in PDA and critical to the growth of RAS/p53 mutant
tumors by sustaining autophagy, via enabling autophago-
some-lysosome fusion. Thus Plac8 provides a mechanistic link
between the cooperation of two common pancreatic cancer
causing gene mutations, KRAS and p53, and the elevated rates
of autophagy critical to tumor growth.
RESULTS
Plac8 Expression Is Induced in Response to Ras and p53
Mutations and Is Critical for Pancreatic Tumor Growth
We have previously identified Plac8, a 112-amino-acid cysteine-
rich protein that is upregulated at the RNA level in PDA (Buchholz
et al., 2005; Lowe et al., 2007), as critical to malignant cell trans-
formation mediated by activated RAS (RasV12) and mutant p53
(mp53) (McMurray et al., 2008). The biochemical function of1144 Cell Reports 7, 1143–1155, May 22, 2014 ª2014 The AuthorsPlac8 is unknown, but the gene has
been linked to efficient killing of phagocy-
tosed bacteria by neutrophils, where it is
enriched in a modified form of lysosomes,
known as the granular fraction, critical for
intracellular antimicrobial action (Ledfordet al., 2007). We confirmed that Plac8 protein levels are induced
synergistically in response to combined expression ofmp53 and
RasV12 in young adult mouse colon (YAMC) cells (Figure 1A) and
can be detected in human pancreatic cancer cell lines (Fig-
ure 1B). Notably, we found that small hairpin RNA (shRNA)-medi-
ated knockdown of Plac8 virtually abolished tumorigenicity
of the CAPAN-2, Panc-1, and Panc10.05 human PDA cell lines
implanted into immunocompromised mice (Figures 1C and S1).
Thus, Plac8 is cooperatively induced in response to mutations in
RAS and p53 and is essential for the cancer phenotype of human
PDA cell lines.
Plac8 Is Predominantly Located to the Lysosome
The subcellular location of Plac8 in epithelial cells was estab-
lished by immunostaining of mp53/Ras cells with Plac8-specific
antibodies, which showed predominantly punctate perinuclear
staining sensitive to Plac8 knockdown and partial colocalization
with staining for the lysosomal protein Lamp2 (Figure 1D). Corre-
spondingly, subcellular fractionation experiments indicated
enrichment of Plac8 protein together with lysosomal proteins
Lamp2 and Rab7 (Figure 1E) (Eskelinen et al., 2002; Gutierrez
et al., 2004; Huynh et al., 2007; Ja¨ger et al., 2004). As observed
for the intralysosomal proteins Lamp2 and Cathepsin D, Plac8 is
resistant to proteinase K digestion, whereas the external lyso-
somal protein Rab7 is degraded (Figure 1F). Thus, in epithelial
cells, Plac8 appears to be a predominantly intravesicular protein,
with significant localization to the lysosomal compartment.
Plac8 Facilitates Autophagosome-Lysosome Fusion
Autophagy is induced upon nutrient stress in normal cells,
whereas in PDA cells autophagy is constitutively activated in
the presence of nutrients (Yang et al., 2011). The mediators of
this activation are unknown. As key late steps of autophagy
involve autophagosome maturation and lysosomal fusion lead-
ing to autolysosome formation, we hypothesized that the locali-
zation of Plac8 to lysosomes may relate to a role in autophagy.
In particular, we wished to address whether Plac8 regulates
lysosomal function and/or fusion with degradative endosomes,
such as phagosomes (as is the case for Plac8 function in neutro-
phils) or autophagosomes. To test the impact of Plac8 on AL
fusion, we compared colocalization of the GFP-labeled microtu-
bule associated protein 1 light chain 3 (LC3), a marker of auto-
phagy that associates with the autophagosome membrane after
processing (Klionsky et al., 2008), and the lysosomal marker
Lamp2 in control and Plac8 knockdown (KD) cells by confocal
analysis (Morselli et al., 2010). Plac8 KD resulted in an 80%
reduction in GFP-LC3/Lamp2 colocalization in murine mp53/
Ras cells and CAPAN-2 PDA cells indicating a reduction in AL
fusion (Figures 2A and 2B). This effect was specific to the reduc-
tion in Plac8 levels, because fusion was rescued by the expres-
sion of an shRNA-resistant Plac8 in either cell type (Figures 2A
and 2B). Moreover, consistent with our interpretation that
Plac8 facilitates AL fusion Plac8 KD resulted in accumulation
of autophagy markers p62 and LC3 both in normal growth
medium and in nutrient-depleted HBSS (Figures 2C and 2D),
with p62 and LC3 reverting to control levels in presence of a
shRNA-resistant Plac8 protein (Figures 2E and 2F).
Diminished AL fusion following Plac8 KD should lead to a
reduction in autophagic flux as indicated by accumulation of
autophagosomes. This was confirmed using the mCherry-
EGFP-LC3 reporter as a probe to estimate the relative numbers
of autophagosomes and autolysosomes, as indicated by yellow
(green+red) and red fluorescence, respectively (Kimura et al.,
2007) in both normal growth medium and in nutrient-depleted
conditions (Figure 2G). In addition, transmission electron micro-
scopy revealed induction of vesicular structures enveloped by
multiple membranes harboring cytosolic content consistent
with accumulated autophagosomes in Plac8 knockdown (KD)
cells that were only rarely found in vector control cells (Figure S2).
Further evidence indicating a role of Plac8 in facilitating auto-
phagic flux comes from experiments in which we introduced
exogenous Plac8 into YAMC cells expressing activated Ras.
Exogenous Plac8 diminished the abundance of autolysosomes,
as indicated by decreased red fluorescence of the mCherry-CEGFP-LC3 reporter (Figure S3A). In addition, levels of endoge-
nous p62 and LC3II proteins were diminished in reporter-free
cells (Figure S3B). In contrast, all these indicators accumulated
to levels above controls in presence of chloroquine (CQ), an in-
hibitor of lysosomal function acting via alkalinization of lyso-
somal pH (Klionsky et al., 2012) (Figures S3A and S3B). Similarly,
both the numbers of endogenous LC3 puncta and their colocal-
ization with Lamp2 increased significantly in presence of CQ and
exogenous Plac8 (Figure S3C). Together, this suggests a sce-
nario in which Plac8 facilitates autophagic flux. Plac8 expression
has minimal impact on p62 and LC3II protein levels in parental
YAMC cells and in mp53 cells, i.e., YAMC cells expressing
mutant p53 in absence of activated Ras (Figures S3D and
S3E). Plac8 thus collaborates with activated Ras to elevate
autophagic flux, though this is not sufficient to cause tumor
growth in mice (Figure S3F).
AL fusion requires the Ras-like GTPase Rab7 and is blocked
by Rab7-T22N, a dominant-negative mutant (Rab7DN), thus
leading to autophagosome accumulation (Ganley et al., 2011;
Gutierrez et al., 2004; Ja¨ger et al., 2004). Similarly, we found
that expression of Rab7DN prevented tumor growth in murine
and human tumor cells, while inducing both accumulation of
p62 and LC3 and decreased colocalization of Lamp2 and
GFP-LC3 (Figures 3A, 3B, and 4), consistent with a block in AL
fusion. In contrast, expression of a dominant-negative mutant
of Rab5a, a gene critical to early endocytosis/phagocytosis
(Bucci et al., 1992; Chen and Wang, 2001; Dinneen and Ceresa,
2004), did not impact AL fusion, p62, or LC3 levels indicating that
inhibition of Rab5a signaling, and early endocytosis did not
effect autophagy (Figures 3C, 3D, 4A, and 4B). As expected,
Rab5aDN inhibited endocytosis, as indicated by a decrease in
uptake of fluorescently labeled dextran in the same cells, further
suggesting that Rab5a-mediated endocytosis is nonessential for
the tumor growth among these cells (Figure S4).
Given the phenotypic similarities in the effects of Plac8 and
Rab7 on autophagy and in promoting AL fusion, we sought to
determine if Rab7 activation could overcome the effects of
Plac8 KD. Exogenous expression of dominant-active Rab7
Q67L (Rab7DA) in the presence of Plac8 KD reversed the tu-
mor-inhibitory effect of Plac8 knockdown (Figures 3E and 3F),
increased Lamp2 and GFP-LC3 colocalization (Figures 4A and
4B), and led to diminished levels of p62 and LC3 (Figures 3E
and 3F), indicative of rescued AL fusion and autophagosomal
processing. The ability of Rab7DA alone to inhibit tumor forma-
tion may thus be due to overactivation of autophagy, an effect
compensated in the presence of Plac8 knockdown (Figures 3E
and 3F).
In summary, our data indicate that knockdown of Plac8
interferes with AL fusion thus preventing downstream auto-
phagosomal processing, whereas the overexpression of Plac8
can promote autophagic flux. Furthermore, activation of Rab7-
dependent AL fusion bypasses the dependence on Plac8 sug-
gesting that Plac8 functions in parallel to Rab7.
Upstream Activation of Autophagy Can Compensate for
Plac8 Knockdown
In order to understand the relationship between Plac8 and
autophagy activation, we tested the capacity of upstreamell Reports 7, 1143–1155, May 22, 2014 ª2014 The Authors 1145
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Figure 2. Plac8KDResults in the Accumula-
tion of Autophagosomes and Autophagy
Markers by Inhibiting Autophagosome-
Lysosome Fusion
(A and B) (A) Murine mp53/Ras transformed and
(B) human CAPAN-2 cells expressing GFP-LC3
and Plac8 shRNA or Plac8 shRNA with exogenous
shRNA resistant Plac8 were nutrient starved in
HBSS for 15 min, fixed, and stained for Lamp2.
Fluorescence quantified by ImageJ. Relative ratios
of autophagosomes fused with lysosomes per
total autophagosomes are shown (±SD, ***p <
0.001, determined by Student’s t test; nR 50 cells
per cell line).
(C–F) Vector control (Vec) or Plac8 shRNA ex-
pressing mp53/Ras (C) and CAPAN-2 cells (D)
were nutrient starved and immunoblotted for p62,
LC3, and Plac8 (b-tubulin loading control). Lysates
of mp53/Ras (E) and CAPAN-2 cells (F) expressing
Vec, Plac8 shRNA, exogenous 3 3 Flag-tagged,
shRNA-resistant Plac8, or Plac8 shRNA with
exogenous 3 3 Flag-tagged, shRNA-resistant
Plac8 were immunoblotted for p62, LC3, Rab7,
and Plac8.
(G) mp53/Ras cells expressing mCherry-EGFP-
LC3 and Vec orPlac8 shRNAwere nutrient starved
(NS) in HBSS or left untreated, fixed, and imaged
via confocal microscopy. Representative images
show a merge of red and green channels (yellow
represents colocalization, i.e., autophagosomes;
red indicates autolysosomes). Fluorescence in-
tensities quantified by ImageJ. Fold changes in
punctae area/cell are indicated (mean ± SD, Stu-
dent’s t test: *p < 0.05; nR 100 cells/cell line).autophagy activation to compensate for Plac8 loss and dimin-
ished rates of AL fusion. We found that ectopic expression of
Atg12, a ubiquitin-like protein covalently linked to Atg5 that
forms a complex essential to autophagosome formation (Miz-
ushima et al., 1998, 2001; Ohsumi, 2001), restored tumor forma-
tion capacity to Plac8 KD cells and increased AL fusion in these1146 Cell Reports 7, 1143–1155, May 22, 2014 ª2014 The Authorscells (Figures 5A–5D). Notably, in cells
expressing ectopic Atg12 in the pres-
ence of Plac8 KD, p62, and LC3-II abun-
dance is restored to levels found in
unperturbed cells (Figures 5A and 5B),
reflective of an autophagy rate restored
to levels observed in the native can-
cer cells. In contrast, exogenous Atg12
expression in the absence of Plac8 KD
was tumor inhibitory (Figures 5A and
5B), possibly due to proapoptotic func-
tions (Rubinstein et al., 2011) or through
hyperactivation of autophagy to levels
inconsistent with survival. The reduction
in steady-state levels of p62 and the
increased ratio of LC3-II/LC3-I protein
in cells expressing ectopic Atg12 sup-
port this latter hypothesis. Thus, whereas
impaired AL fusion caused by Plac8 KDimpedes PDA growth, upstream activation of the pathway can
compensate for this. Moreover, consistent with an essential
role of autophagy for the cancer phenotype, Atg12 KD inhibited
tumor formation together with a decreased ratio of LC3-II/ LC3-I
and p62 accumulation (Tanida et al., 2002) in both mp53/Ras
and CAPAN-2 cells (Figure S5).
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Figure 3. Activated Rab7 Rescues Cancer Phenotype in Plac8 KD Cells
Murine mp53/Ras cells (A, C, and E) and human CAPAN-2 cells (B, D, and F) were grafted into CD-1 nudemice, and tumor growth wasmonitored. Mean values of
tumor volume ± SD and Student’s t test at final time point are indicated (***p < 0.001; **p < 0.01; *p < 0.05; nR 9 tumors per condition). Cells expressing 33 Flag-
tagged Rab7 DN (Rab7T22N) or vector control (Vec) (A&B), 33 Flag-tagged Rab5a DN (Rab5aS34N) or Vec (C&D), and 33 Flag-tagged Rab7 DA, Plac8 shRNA,
Plac8 shRNA with 33 Flag-tagged Rab7 DA or Vec (E and F) were used. Corresponding cell lysates were immunoblotted for p62, LC3, Rab5 or Rab7 (A–F), and
Plac8 in E&F (b-tubulin loading control).Increased expression of Plac8 was noted in mp53/Ras cells in
response to ectopic Rab7DA or ATG12 expression (Figures 3E,
3F, 5A, and 5B). This may occur as a response to stress, or as
part of the program stimulating autophagy, considering Plac8
is able to stimulate autophagic flux in the presence of activated
Ras (Figure S3).
Synergistic Induction of Autophagy byActivatedRas and
Mutant p53
Mutations in both KRAS and p53 have been linked with alter-
ations in autophagy; however, their combined impact and the
associated mechanisms are unknown (Guo et al., 2011; LiveseyCet al., 2012; Lock et al., 2011; Morselli et al., 2011; Tasdemir
et al., 2008; Yang et al., 2011). Given the identification of
Plac8 as a gene cooperatively upregulated by these mutations
and its role in promoting AL fusion, we asked if autophagy rates
would be regulated similarly by concurrent oncogenic muta-
tions. To test this possibility, we compared accumulation of
LC3 punctae following chloroquine treatment in YAMC cells,
mp53, Ras, and mp53/Ras cells using the mCherry-EGFP-LC3
reporter. Notably, a significant increase in punctae was de-
tected only in mp53/Ras cells, indicating that autophagic flux
is induced synergistically by mutant p53 and activated Ras
(Figure 6).ell Reports 7, 1143–1155, May 22, 2014 ª2014 The Authors 1147
AB
Figure 4. ActivatedRab7Rescues Autopha-
gosome-LysosomeFusion in Plac8 KDCells
Murine GFP-LC3-mp53/Ras cells (A) and human
GFP-LC3-CAPAN-2 cells (B) expressing vector
control, Plac8 shRNA, 3 3 Flag-tagged Rab7 DN,
33 Flag-taggedRab5aDN, 33 Flag-taggedRab7
DA, or Plac8 shRNA and 33 Flag-tagged Rab7DA
were nutrient starved in HBSS for 15 min, fixed,
stained for Lamp2, and imaged via confocal mi-
croscopy. Colocalization was determined and
quantified by ImageJ. The ratios of autophago-
somes fused with lysosomes (colocalized signal)/
total autophagosomes are indicated (mean ± SD;
Student’s t test; ***p < 0.001; nR 50 cells/cell line).
1148 Cell Reports 7, 1143–1155, May 22, 2014 ª2014 The Authors
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Figure 5. Overexpression of Atg12 Rescues
Plac8 KD Inhibition of Cancer Phenotype
and Autophagosome-Lysosome Fusion
Murine mp53/Ras cells (A) and human CAPAN-2
cells (B) were grafted into CD-1 nude mice and
tumor growth was monitored. Mean values of tu-
mor volume ±SD and Student’s t test at final time
point are indicated (***p < 0.001; nR 9 tumors per
condition). Cells expressing vector control (Vec),
3 3 Flag-tagged Atg12, Plac8 shRNA, or Plac8
shRNA and 3 3 Flag-tagged Atg12 were used.
Corresponding cell lysates were immunoblotted
for p62, LC3, Atg12, and Plac8. GFP-LC3-mp53/
Ras cells (C) and GFP-LC3-CAPAN-2 cells (D)
expressing Vec, Plac8 shRNA, or Plac8 shRNA
and 3 3 Flag-tagged Atg12 were nutrient starved
in HBSS for 15 min fixed, stained for Lamp2, and
imaged via confocal microscopy. Colocalization
was determined and quantified by ImageJ. The
ratios of autophagosomes fused with lysosomes
(colocalized signal)/total autophagosomes are
indicated (mean ± SD; Student’s t test ***p <
0.001; **p < 0.01; nR 50 cells/line).Plac8 Depletion Does Not Alter Lysosomal pH
Inhibitors of AL fusion such as bafilomycin A1 or CQ act via dis-
rupting lysosomal pH (Klionsky et al., 2012; Yamamoto et al.,
1998). Plac8 KD, however, had no effect on lysosomal pH (Fig-
ure S6A). Consistent with this finding lysosomal pH-dependent
endocytic degradation of epidermal growth factor receptors
(EGFRs) (Ganley et al., 2011) was unaffected by Plac8 KD (Fig-
ure S6B). Similarly, Plac8 KD has no detectable effect on endo-
cytosis, as visualized by cellular dextran uptake (Figure S6C).
Taken together, our data suggest that Plac8 functions via mech-
anisms that modulate rates of AL fusion without affecting lyso-
somal pH or endocytic degradation.
Inhibition of autophagosome-lysosome fusion by CQ has also
been associated with an increase in cellular reactive oxygen spe-
cies (ROS) suggestinga role for autophagy incopingwithoxidative
stress (Yang et al., 2011). Although we found CQ-mediated
increases of ROS levels in mp53/Ras cells, Plac8 KD had no
impact on cellular ROS, as detectable by DCF staining (Figures
S6D and S6E), suggesting that inhibition of autophagosome-lyso-
some fusion is not necessarily associatedwith increases in cellular
ROS.Conversely, inductionofcellularROS followingCQexposure
thus may be unrelated to modulation of autophagic flux.Cell Reports 7, 1143–115Mutation of Plac8 Extends Survival
in a Kras-p53 PDA-Engineered
Mouse Model
To extend our findings in xenograft
models, we evaluated the importance of
Plac8 in PDA progression and biology
using a Pdx1-Cre; LSL-KrasG12D; p53L/+
genetically engineered mouse PDA
model. This model exhibits successive
stages of cancer progression (referred to
as pancreatic intraepithelial neoplasia or
PanIN I–III) leading to PDA, that typifies
the human disease. Tumor progressionis associated with loss of the wild-type p53 allele, and thus all
ensuing tumors are p53 null (Bardeesy et al., 2006a). Cohorts
of Pdx1-Cre; LSL-KrasG12D; p53L/+ mice with concurrent germ-
line Plac8+/+, or Plac8/ mutations, henceforth referred to as
PDA-Plac8wt and PDA-Plac8null were created using established
strains (Bardeesy et al., 2006a; Ledford et al., 2007). Mice were
born at expected Mendelian ratios and were indistinguishable
from each other with regards to outward appearance and activity
through the first 8weeks of life as expected (Ledford et al., 2007).
Individuals were followed longitudinally until signs of illness
necessitated necropsy (see Experimental Procedures). Overall
survival of the PDA-Plac8null cohort (OS 27.9 weeks) was signif-
icantly longer than the PDA-Plac8wt cohort (OS 17.0 weeks, p =
0.0006) (Figure 7A) demonstrating in vivo that genetic inactiva-
tion of Plac8 impedes cancer progression and resulting death.
Thus, Plac8 has a central role in PDA pathogenesis.
The increased survival of the PDA-Plac8null cohort could be
due to an impact on tumor progression in the early stages of tu-
mor initiation, namely, the formation of PanIN precursor lesions,
or in the later stages of fully advanced PDA growth. To differen-
tiate these possibilities, we conducted a histological survey of
the pancreas of PDA-Plac8null and PDA-Plac8wt at 9 weeks of5, May 22, 2014 ª2014 The Authors 1149
Figure 6. Synergistic Induction of Autophagic Flux by Mutant p53
and Activated Ras
YAMC, mp53, Ras, and mp53/Ras cells expressing mCherry-EGFP-LC3 were
exposed to 25 mM chloroquine (CQ) for 24 hr or left untreated, fixed, and
imaged using confocal microscopy. Representative images show themerge of
red and green channels, with yellow representing signal colocalization. Auto-
phagosomes (yellow) and autolysosomes (red) quantified using ImageJ. Fold
changes in punctae areas/cell are indicated (mean ± SD; Student’s t test;
**p < 0.01; *p < 0.05; nR 50 cells/line).age just prior to the onset of lethal advanced tumors. Quantifica-
tion of normal ducts, as well as, early and late PanIN revealed no
significant differences in the prevalence of premalignant lesions
between the groups (Figures 7B and S7). Therefore, Plac8 loss
has minimal effect on the early stages of tumor initiation, indi-
cating that Plac8 rather contributes to the progression of
advanced PanINs and PDA.
To gain further insight into the relationship between Plac8,
autophagy control, and PDA pathogenesis, we crossed a GFP-
LC3 transgenic strain with our Kras-p53 model, enabling us to
measure autophagy in vivo (Kuma et al., 2004). In this model
(GFP-LC3; Pdx1-Cre; LSL-KrasG12D; p53L/+), in which the wild-1150 Cell Reports 7, 1143–1155, May 22, 2014 ª2014 The Authorstype p53 allele is lost during the course of PanIN progression
toward cancer (Bardeesy et al., 2006a), we found an increase
in LC3 punctae, indicating increased numbers of epithelial auto-
phagosomes, with each successive histological stage of cancer
progression, with highest levels in PDA, and virtually no punctae
in normal ducts or low grade PanIN-1 (Figure 7C). Consistent
with this finding, immunofluorescent staining of histological sec-
tions indicated Plac8 expression in PanINs and PDA, whereas
Plac8 staining is not detectable in normal pancreatic ducts. In
addition, Plac8 staining colocalizes with Lamp2 staining, con-
firming lysosomal localization of Plac8 in PDA (Figures 7D and
7E) Taken together, the marked and specific activation of auto-
phagy in advanced PDA matches well with the specific impact
of Plac8 inactivation on the later stages of disease.
DISCUSSION
Synergistic regulation downstream of cooperating oncogenic
mutations has emerged as a reliable indicator of genes critical
to malignant cell transformation in a variety of contexts including
cancer-initiating cells (McMurray et al., 2008; Ashton et al.,
2012). Here, we identify such a gene, Plac8, as a regulator of au-
tophagosome-lysosome fusion required for PDA growth, thus
providing a mechanistic link between oncogenic mutations and
the activation of autophagy in cancer. Activated by oncogenic
KRAS and p53 loss of function, two of the most commonly
occurring mutations in cancer, Plac8 expression is required
for growth of human pancreatic cancer cells as xenografts in
mice, as well as activation of autophagy in vitro and in vivo where
we observe that both RAS and p53 mutations are critical for
elevated autophagy rates. Our data also suggest that the role
of Plac8 in facilitating autophagy is critical to the cancer pheno-
type, as the requirement of Plac8 for both tumorigenicity and
autophagy can be compensated by overexpression of Atg12, a
gene critical for autophagosome formation (Mizushima et al.,
1998), or by constitutively activated Rab7, a gene encoding a
GTP-binding protein stimulating autophagosome-lysosome
fusion (Gutierrez et al., 2004; Ja¨ger et al., 2004). This is consis-
tent with an interpretation that tumor growth of Plac8-deficient
cells is compromised due to suboptimal autophagic flux.
Notably, we also show that Plac8 may offer a potential therapeu-
tic window and point of intervention, as Plac8 germline mutation
in an engineered PDA model inhibits cancer progression and
significantly improves survival while having a minimal impact
on the overall fitness of the animals. This suggests that Plac8,
and regulation of autophagosome-lysosome fusion, has specific
relevance to regulation of autophagy during malignant cell trans-
formation. Independent support for the oncogenic potential of
the Plac8 gene comes from several in vivo genetic screens in
which Plac8 has been identified repeatedly as a target for retro-
viral insertion mutagenesis, implicating its deregulation as a
driving force in carcinogenesis (Kool et al., 2010; Williams
et al., 2006).
Plac8 is a lysosomal protein that facilitates autophagosome-
lysosome fusion without affecting endocytic protein degradation
and lysosomal pH. This is in contrast to Rab7 and SNARE pro-
teins, such as VAMP8, that impact both autophagosome-lyso-
some fusion and endocytic protein degradation (Furuta et al.,
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Figure 7. Plac8 Mutation Impedes
Advanced Tumor Progression in the Kras-
p53 Mouse PDA Model
(A) Kaplan-Meier analysis of cohorts of Pdx1-
Cre;LSL-KrasG12D;p53L/+ mice with concurrent
germline Plac8+/+ or Plac8/ mutations. Overall
survival is increased in Plac8null cohort (27.9weeks)
compared with Plac8wt (OS 17. weeks, p = 0.0006).
(B) Whole pancreatic histological analysis of
Pdx1-Cre;LSL-KrasG12D;p53L/+ mice with concur-
rent germline Plac8/ mutations (n = 6) versus
Plac8 WT (n = 10) at 9 weeks of age demonstrated
similar burdens of PanIN. Data are presented as a
fraction of the total with confidence intervals.
Three of ten wild-type compared to 0/6 Plac8/
harbored advanced PDA.
(C) Epithelial cell GFP punctae (white arrows)
harbored within normal ducts, pancreatic intra-
epithelial neoplasia I and III (PanIN I&III), and PDA
(n = 50 cells/lesion) were quantified from cohort of
Pdx1-Cre; LSL-KrasG12D;p53L/+;GFP-LC3 mice
(n = 6 mice; significance determined by the Mann-
Whitney test ***p < 0.001; **p < 0.01; *p < 0.05).
(D) Immunoflourescent staining of Plac8 in normal
pancreatic duct, PanIN (white arrow) and PDA
from Pdx1-Cre; LSL-KrasG12D;p53L/+ mice. Adja-
cent H&E-stained sections were evaluated to
determine histologic classification.
(E) PDA tissue from Pdx1-Cre;LSL-KrasG12D;p53L/+
stained with Plac8 and Lamp2 antibodies, visual-
ized with Alexa 488 (green) and Alexa 555 (red),
respectively.2010; Gutierrez et al., 2004; Klionsky et al., 2012; Wong et al.,
1998). The apparently minimal impact of Plac8 deficiency on
normal physiologic processes (Ledford et al., 2007) fits well
with the mutant phenotypes of several other genes involved in
the autophagosome maturation including Lamp2 and Tecpr1
(Chen et al., 2012; Eskelinen et al., 2002; Ogawa et al., 2011;
Tanaka et al., 2000). Unlike many Atg-family mutant mice, which
are not viable (Komatsu et al., 2005; Kuma et al., 2004), Plac8,
Lamp2, and Tecpr1 mutant mice can all survive through adult-
hood, though all suffer from a diminished capacity to clear infec-
tions, due to defects in lysosomal function (Beertsen et al., 2008;
Binker et al., 2007; Ledford et al., 2007; Ogawa et al., 2011).
Thus, later stages of autophagy and autophagosomematuration
may provide a variety of attractive therapeutic opportunities
where inhibition of steps in this process are likely better tolerated
by normal tissues but not by tumors that depend on a high auto-
phagic rate.
Plac8 was identified originally as a leukocyte inhibitory factor
regulated gene in the mouse uterus and also in genome-wide
expression analysis of the placenta, from where its name is
derived (Galaviz-Hernandez et al., 2003). It has been functionally
ascribed to the regulation of a number of distinct cellular pro-
cesses (Rogulski et al., 2005; Wu et al., 2010). Plac8 knockout
mice have been found to suffer increased adiposity at advanced
ages leading to the discovery of a role in brown fat differentiation
through induction of C/EBPbeta expression (Jimenez-Preitner
et al., 2011). Of note, we did not find significant differences inClevels of C/EBPbeta expression among PDA cell lines with or
without Plac8. Because our data point toward an extranuclear
location in epithelial cells, within the lysosomal compartment
where it facilitates autophagosome-lysosome fusion, it seems
plausible that Plac8 may have differing roles among different
cell types.
Here, we find that concurrent mutation of KRAS and p53 is
critical for maximal induction of autophagy, and correspond-
ingly, we see a stepwise incremental increase in LC3 puncta
in vivo with each histological stage through the course of PDA
progression. Thus, we find that the cooperative effects of
KRAS and p53 drive activation of autophagy rather than either
mutation alone. This is consistent with established associations
between autophagy dependence and RAS mutant tumor cell
lines, many of which harbor p53 mutations (Guo et al., 2011;
Lock et al., 2011; O’Dell et al., 2012; Yang et al., 2011). Others
have reported conflicting roles of p53 in regulating autophagy
(Morselli et al., 2011; Tasdemir et al., 2008), with a recent report
showing that in a setting of homozygous p53 deletion during
embryonal development loss of autophagy accelerates pancre-
atic tumor progression (Rosenfeldt et al., 2013). We elected to
study autophagy in vivo using a model in which loss of p53 func-
tion occurs in a stepwise progressive manner relying on the
spontaneous loss of a heterozygous WT p53 allele (Bardeesy
et al., 2006a) as a late mutational event mimicking human PDA
progression (Hruban et al., 2001; Lu¨ttges et al., 2001). In this
context, we observe full autophagy activation at later stages ofell Reports 7, 1143–1155, May 22, 2014 ª2014 The Authors 1151
tumor formation. Correspondingly, it is at this point in advanced
PanIN and PDA, when autophagy ismost active, that we observe
a delay in tumor progression in the absence of Plac8. In contrast,
we do not see any effect of loss of Plac8 in a PDAmodel in which
both copies of the conditional p53 allele are somatically mutated
during embryogenesis (Figure S8), suggesting that the timing of
complete p53 loss in the natural history and progression of PDA
impacts the resulting tumor’s dependencies.
Pancreatic ductal adenocarcinoma (PDA) remains a signifi-
cant challenge clinically despite iteration of many of the path-
ways and processes downstream of the signature genetic
lesions (Hezel et al., 2006; Hidalgo, 2010). Further highlighting
this is the fact that the most significant treatment advance in
the past decade has come from a new combination of traditional
chemotherapies rather than any particular novel genetic or
biologic revelation (Conroy et al., 2011). Although insights into
improving drug delivery, modulation of the tumor microenvi-
ronment, and additional downstream effectors of KRAS have
recently pointed to alternative therapeutic strategies, new pro-
cesses and targets critical to PDA growth are needed (DeNicola
et al., 2011; Frese et al., 2012; Olive et al., 2009; Provenzano
et al., 2012; Rhim et al., 2012). Although pharmacologic inhibition
of autophagy is under ongoing evaluation clinically, there are
limited agents available; moreover, autophagy plays a critical
role in normal tissue homeostasis and energy balance making
the identification of a therapeutic window potentially difficult.
Thus, regulators and effectors of autophagy specific to tu-
mors, such as Plac8, could potentially offer valuable targets for
intervention.
EXPERIMENTAL PROCEDURES
Cells
YAMC,mp53, Ras,mp53/Ras cell derivation andmaintenancewere described
previously (McMurray et al., 2008; Xia and Land, 2007). CAPAN-2, PANC-1,
and Panc10.05 cell lines were obtained from ATCC.
Antibodies and Compounds
The following antibodies were used: rabbit polyclonal antibody raised against
the c-terminal 16 amino acids of murine Plac8 (Ledford et al., 2007) (Pocono
Rabbit Farm & Laboratories), rabbit polyclonal anti-b-Tubulin antibody
(H-235, Santa Cruz Biotechnology), rat monoclonal anti-Lamp2 antibody
(GL2A7, Abcam), mouse monoclonal anti-Rab7 antibody (R8779, Sigma),
rabbit polyclonal anti-LC3B antibody (L7543, Sigma), mouse monoclonal
anti-RhoA antibody (sc-418, Santa Cruz), goat polyclonal anti-cathepsin D
antibody (sc-6486, Santa Cruz), guinea pig polyclonal anti-p62 antibody
(GP62-C, PROGEN), mousemonoclonal anti-33 Flag antibody and HRP-con-
jugated anti-3 3 Flag antibody (F2426 and A8592, Sigma), rabbit polyclonal
anti-Rab5 antibody (ab18211, Abcam), rabbit polyclonal anti-Atg12 antibody
(A8731, Sigma), and EGFR antibody (sc 03).
The following compounds were used: bafilomycin A1 (Sigma B1793),
chloroquine (Sigma 6628), and cycloheximide (Sigma C7698, Lysosensor
Yellow Blue DND-160 and DCF-DA (Molecular Probes, L-7545 and C6827,
respectively).
Plasmids
Plasmids for retroviral Plac8 KD and shRNA-resistant Plac8 expression were
described previously (McMurray et al., 2008). cDNAs for Rab7, Rab5a, and
Atg12 were PCR cloned in pBabe-hygro containing an in-frame, N-terminal
3 3 Flag tag and sequence verified. Dominant-negative and activated Rab7
and Rab5a mutants were generated via site-directed mutagenesis and
sequence verified. N-terminal 3 3 Flag-tagged DN Rab7, DA Rab7, DN1152 Cell Reports 7, 1143–1155, May 22, 2014 ª2014 The AuthorsRab5a, and Atg12 were PCR cloned in pLenti/Ubc/V5 (Invitrogen) and
sequence verified. cDNA for LC3 was PCR cloned in pEGFP (Clontech
Laboratories) and subsequently PCR cloned into lentiviral vector FG12. The
mCherry-EGFP-LC3 puro construct (Addgene 22418) (N’Diaye et al.,
2009) was cloned into pBabe-hygro. Atg12 shRNA molecules were designed
(http://jura.wi.mit.edu/bioc/siRNAext/home.php) and cloned into the pSuper-
retro system (Oligoengine). Atg12 lentiviral KD constructs were obtained from
Openbiosystems.
Immunofluorescent Staining of Cells
Cells were plated onto collagen-1-coated 22 mm glass coverslips (BD Biosci-
ences). Cells were fixed and incubated with primary antibody overnight at 4C
while shaking followed by appropriate secondary antibodies. Immunostained
cells were (1) washed three times for 10 min with PBS, (2) mounted in
VectaShield Mounting Media (Vector Laboratories), and (3) analyzed and
imaged using a SP5 Leica inverted confocal microscope.
Subcellular Fractionation and Lysosome Isolation
mp53/Ras cells were grown for 2 days at 39C in RPMI with 10% (v/v) FBS,
before pelleting at 1,200 rpm for 5min at 4C. A fraction was retained and lysed
in RIPA buffer for thewhole-cell lysate (WC) sample. Lysosomeswere then iso-
lated using a Lysosomal Isolation Kit (Sigma). In short, the cell pellet was resus-
pended, then homogenized in a Dounce homogenizer, and centrifuged at
1,000 3 g for 10 min. The pellet was saved as the nuclear fraction (N) sample.
The supernatant was then centrifuged at 20,000 3 g for 20 min, and superna-
tant was removed and saved as the cystosolic fraction (C). The pellet was
resuspended in a small aliquot as the crude lysosomal fraction (CL). To sepa-
rate lysosomes from other organelles 505 ml of Optiprep and 275 ml of Optiprep
dilution buffer were added per 800 ml of resuspended crude lysosomal fraction.
CaCl2 was added to final concentration of 8mM, followed by 15min incubation
on ice and centrifugation at 5000 3 g for 10 min at 4C. Purified lysosomal
fraction (L) (supernatant) and microsomal pellet (M) were retained. Pellets
were resuspended in RIPA; protein was determined by Bradford assay. SDS
sample buffer was added to all samples.
Proteinase K Treatment of Lysosomes
The crude lysosomal fraction was isolated as described above and resus-
pended in 50 mM Tris buffer (pH 7.4). Crude lysosomal fractions were divided
and treated for 30 min at 37C with (1) buffer, (2) 0.5 mg/ml PK, (3) 0.5 mg/ml
PK + 1.0% Triton X-100. Samples were then placed on ice, PK activity was
quenched with 1 mM phenylmethanesulfonylfluoride, and SDS sample buffer
was added.
Xenograft Assays
Matrigel (BD Biosciences) was mixed with PANC-1 and Panc10.05 cell/
medium mixture in a 1:1 ratio. Cell mixtures were then injected bilaterally
into the flanks of CD-1 nude mice (Crl:CD-1-Foxnnu, Charles River Labora-
tories) in the following cell numbers: mp53/Ras, 5 3 105 cells, and CAPAN-
2, 5 3 105 cells. Cell mixtures were injected into the flanks of NOD/SCID
mice (Charles River Laboratories) in the following cell numbers per injection:
PANC-1, 2.5 3 106 cells, and Panc10.05, 1 3 106 cells. Tumor size was
measured every 7 days by caliper and volume calculated by the formula vol-
ume = (4/3)Pr3, using the average of two orthogonal radius measurements;
significance of difference in tumor size was calculated by t test.
Quantification of GFP-LC3 and mCherry-EGFP-LC3 Punctae, and of
Lamp2/GFP-LC3 Colocalization
Cells were fixed, stained, mounted, and imaged by the methods described
above. GFP-LC3 punctae were determined using the ImageJ plug-in Water-
shed Segmentation. The image produced by selecting Object/Background
binary was inverted and overlayed on top of the GFP-LC3 image. The resulting
imagewas quantified bymeasuring themean green and blue signals per image
and dividing the blue signal by the total green signal to get the amount of punc-
tae per total GFP-LC3 expressed in the cell and then normalized to the mean
YAMC ratio of punctae formation. To quantify GFP-LC3 colocalization, the
ImageJ plug-in Co-localization Finder was used to determine colocalization
(in white) of red (Lamp2) and green (GFP-LC3) signal. The mean colocalized
signal were then divided by the GFP-LC3 signal to derive a ratio of colocaliza-
tion per GFP-LC3 signal, and these ratios were then normalized to the mean
values derived from vector control or YAMC cells. The mCherry-EGFP-LC3
reporter was used to determine ratios of autophagosomes (red and green
colocalized signal) and autolysosomes (red signal only). The Red and Green
Punctae Co-localization plug-in in ImageJ was used to derive the puncta areas
per cell. The area value for autolysosomes was determined by subtracting the
red and green colocalized signal from the red puncta area and normalized to
themean of themCherry-EGFP-LC3 puncta area of vector control or untreated
control samples.
Mice
Mutant Mouse Strains
All animal studies were conducted in accordance with the AAALAC accredited
University Committee on Animal Resources (UCAR). All mouse strains used in
these studies have been previously described and characterized (Bardeesy
et al., 2006a; Kuma et al., 2004; Ledford et al., 2007). Specifically KrasG12D,
p53L/L, Plac8/, GFP-LC3, and Pdx-Cre mutant strains were intercrossed
to achieve the desired cohorts as outlined above. The genetic background
was mixed. Individual mice within experimental cohorts were followed until
signs of illness including poor grooming, abdominal bloating, diminished
activity, or weight loss at which point a full necropsy was performed followed
by histological analysis.
Histology and In Vivo GFP-LC3- Analysis
Aboard-certified pathologist with a specialization in pancreatic histopathology
independently reviewed and classified tumors. Lymph nodes, lungs, and
spleen were included in a survey for metastasis in all individuals with tumors.
To determine the extent of PanIN formation at 9 weeks of age, the whole
pancreas from wild-type and Plac8-null Kras-p53 PDA mice (n = 6–10/ group)
was sectioned lengthwise. Ductal structures were analyzed using hematoxylin
and eosin (H&E)-stained sections and classified as normal, PanIN1, or PanIN3.
To determine formation of LC3 punctae, in vivo frozen sections from com-
pound GFP-LC3 Kras-p53 mutant pancreas were analyzed as previously
described by confocal microscopy (Kuma et al., 2004). Adjacent H&E-stained
sections were evaluated by C.L.W.-M. to determine histologic classification
(normal ducts, PanIn1 or 3, or PDA). In summary n = 3 mice encompassing
each histologic type of lesion were evaluated. Punctae and nuclei from ductal
structures (normal and PanIN1–3) and well-differentiated PDA (in which a
distinction could be made histologically between tumor and stroma) were
manually counted as well as determined by ImageJ. Because results between
manual counts and those determined by ImageJ analysis were consistent,
ImageJ analysis is presented.
Survival Analysis
Survival was determined using the Kaplan-Meier method, and comparisons
between groups were determined using the log-rank test. All statistical
analyses were performed using Prism statistical software version 4.0a May
11, 2003. Animals that displayed signs of illness and were found to have
advanced cancers on necropsy were included as events as were all animals
that died prior to developing signs of illness that had a pancreatic mass and
histological diagnosis of adenocarcinoma identified at autopsy. Animals that
died for reasons other than advanced cancer, as determined by the absences
of pancreatic pathology on autopsy, were censored.
Immunofluorescent Staining of Tumor Sections
Whole pancreas from wild-type and Plac8-null Kras-p53 PDA mice was
paraffin embedded and sectioned lengthwise. Slides were baked in a 60C
oven for 1 hr followed by routine deparafinization. Antigen retrieval was then
performed in a pressure cooker with 13 Rodent decloaker (Biocare Medical).
Slides were blocked with 3% hydrogen peroxide, rinsed well in phosphate
buffered saline, and incubated with Plac8 antibody at 1:500 dilution at room
temperature and then anti-rabbit Alexa 488 secondary antibody for 30 min
at room temperature. The tissue sections were next incubated with the
Lamp2 and anti-rat Alexa 555 secondary antibody sequentially as described
above. The sections were rinsed again, dehydrated in 100%ethanol, mounted,
and imaged using confocal microscopy.CSUPPLEMENTAL INFORMATION
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